Proto Labs, Inc. (PRLB) Reaches $112.95 After 6.00% Up Move; Buckhead Capital Management Has Cut Cvs Health (CVS) Stake

February 15, 2018 - By Kurt Siggers

Buckhead Capital Management Llc decreased Cvs Health Corp (CVS) stake by 17.09% reported in 2017Q3 SEC filing. Buckhead Capital Management Llc sold 18,920 shares as Cvs Health Corp (CVS)’s stock declined 4.23%. The Buckhead Capital Management Llc holds 91,764 shares with $7.46 million value, down from 110,684 last quarter. Cvs Health Corp now has $71.25 billion valuation. The stock increased 0.77% or $0.54 during the last trading session, reaching $70.33. About 4.33M shares traded. CVS Health Corporation (NYSE:CVS) has declined 24.40% since February 15, 2017 and is downtrending. It has underperformed by 41.10% the S&P500.

The stock of Proto Labs, Inc. (NYSE:PRLB) is a huge mover today! The stock increased 3.81% or $4.15 during the last trading session, reaching $112.95. About 83,827 shares traded. Proto Labs, Inc. (NYSE:PRLB) has risen 6.14% since February 15, 2017 and is uptrending. It has underperformed by 10.56% the S&P500.The move comes after 5 months positive chart setup for the $3.01 billion company. It was reported on Feb, 15 by Barchart.com. We have $119.73 PT which if reached, will make NYSE:PRLB worth $180.60M more.

Since December 11, 2017, it had 0 insider purchases, and 2 selling transactions for $430,523 activity. Gawlick Rainer sold $51,375 worth of stock. The insider Bodor Robert sold 4,000 shares worth $379,148.

Proto Labs, Inc., together with its subsidiaries, operates as an e-commerce enabled digital maker of custom parts for prototyping and short-run production in the Unites States, Europe, and Japan. The company has market cap of $3.01 billion. The firm utilizes injection molding, computer numerical control machining, and three-dimensional printing to manufacture custom parts for developers and engineers who use 3D computer-aided design software to design products in the medical, aerospace, computer/electronics, consumer products, industrial machinery, and other markets. It has a 58.52 P/E ratio.

Investors sentiment decreased to 1.27 in 2017 Q3. Its down 0.07, from 1.34 in 2017Q2. It dived, as 14 investors sold Proto Labs, Inc. shares while 56 reduced holdings. 31 funds opened positions while 58 raised stakes. 26.02 million shares or 0.95% less from 26.27 million shares in 2017Q2 were reported. Advisory Rech reported 0.04% stake. 140 were accumulated by Carroll. Mairs And Power Inc invested in 0.48% or 492,952 shares. Moreover, National Bank Of Montreal Can has 0% invested in Proto Labs, Inc. (NYSE:PRLB) for 30,256 shares. Greenleaf Tru owns 632 shares or 0% of their US portfolio. Oppenheimer Asset Management Incorporated holds 0.12% or 55,935 shares. Profund Advsr Ltd Liability Corp reported 3,352 shares stake. 53,127 are owned by Us Commercial Bank De. Lpl Financial Ltd Limited Liability Company invested in 0% or 3,517 shares. Evercore Wealth Management Ltd Liability holds 0% of its portfolio in Proto Labs, Inc. (NYSE:PRLB) for 65 shares. Riverbridge Prtn Lc holds 2.93% in Proto Labs, Inc. (NYSE:PRLB) or 1.85 million shares. Maverick Capital Limited holds 0.06% or 58,940 shares. Dorsey & Whitney Trust Co Limited Liability Corporation, a South Dakota-based fund reported 13,995 shares. Quantitative Invest Management invested in 0.01% or 11,100 shares. Invesco Ltd accumulated 0% or 31,981 shares.

Among 8 analysts covering Proto Labs (NYSE:PRLB), 3 have Buy rating, 0 Sell and 5 Hold. Therefore 38% are positive. Proto Labs has $92.0 highest and $45 lowest target. $78.67’s average target is -30.35% below currents $112.95 stock price. Proto Labs had 15 analyst reports since August 26, 2015 according to SRatingsIntel. Dougherty & Company downgraded the stock to “Sell” rating in Wednesday, August 31 report. The rating was maintained by Needham with “Hold” on Thursday, October 26. The stock of Proto Labs, Inc. (NYSE:PRLB) earned “Equal-Weight” rating by Stephens on Friday, April 29. The firm earned “Outperform” rating on Wednesday, August 26 by Oppenheimer. The company was maintained on Friday, October 13 by Piper Jaffray. The rating was maintained by Piper Jaffray with “Hold” on Thursday, October 26. The rating was maintained by Craig Hallum on Monday, November 27 with “Hold”. Canaccord Genuity upgraded Proto Labs, Inc. (NYSE:PRLB) rating on Thursday, October 15. Canaccord Genuity has “Buy” rating and $75 target. The rating was maintained by Piper Jaffray on Monday, February 5 with “Hold”. The stock has “Hold” rating by Piper Jaffray on Thursday, July 27.

Investors sentiment decreased to 0.88 in 2017 Q3. Its down 0.04, from 0.92 in 2017Q2. It fall, as 60 investors sold CVS shares while 571 reduced holdings. 88 funds opened positions while 466 raised stakes. 801.45 million shares or 0.31% less from 803.96 million shares in 2017Q2 were reported. Zurcher Kantonalbank (Zurich Cantonalbank) invested 0.33% in CVS Health Corporation (NYSE:CVS). Allsquare Wealth Mngmt Ltd Liability Com holds 2,232 shares or 0.15% of its portfolio. Waldron Limited Partnership reported 0.1% in CVS Health Corporation (NYSE:CVS). Advisors Capital Ltd Liability Co owns 0.98% invested in CVS Health Corporation (NYSE:CVS) for 148,676 shares. First Citizens Bancshares And Tru Com, a North Carolina-based fund reported 69,519 shares. Mechanics Retail Bank Department invested in 53,519 shares. Euclidean Techs Mngmt has 1.51% invested in CVS Health Corporation (NYSE:CVS) for 19,407 shares. South State Corp, South Carolina-based fund reported 101,856 shares. Moreover, Stearns Finance Svcs Gru has 0.2% invested in CVS Health Corporation (NYSE:CVS) for 9,837 shares. The Florida-based Sawgrass Asset Mngmt Ltd Liability has invested 0.11% in CVS Health Corporation (NYSE:CVS). Tiemann Investment Limited Liability Company stated it has 4,400 shares. Connable Office has 22,985 shares for 0.38% of their portfolio. Moreover, Welch Cap Llc Ny has 2% invested in CVS Health Corporation (NYSE:CVS) for 72,954 shares. 214,835 were accumulated by St Germain D J. Renaissance Gru Limited Liability Company stated it has 1.12% in CVS Health Corporation (NYSE:CVS).

Among 25 analysts covering CVS Health (NYSE:CVS), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. CVS Health had 72 analyst reports since July 22, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Citigroup given on Tuesday, February 13. The stock has “Hold” rating by Robert W. Baird on Thursday, January 4. The stock has “Peer Perform” rating by Wolfe Research on Monday, August 14. The firm has “Outperform” rating by Oppenheimer given on Thursday, December 17. As per Tuesday, November 7, the company rating was maintained by Loop Capital. The stock of CVS Health Corporation (NYSE:CVS) earned “Hold” rating by Wolfe Research on Wednesday, August 16. As per Monday, December 4, the company rating was maintained by RBC Capital Markets. Jefferies maintained the stock with “Hold” rating in Wednesday, August 16 report. On Wednesday, July 22 the stock rating was maintained by Deutsche Bank with “Hold”. The firm has “Buy” rating given on Friday, October 13 by SunTrust.

Since August 16, 2017, it had 0 insider buys, and 6 selling transactions for $58.12 million activity. SWIFT RICHARD J sold $199,050 worth of stock or 2,500 shares. Foulkes Helena also sold $3.22M worth of CVS Health Corporation (NYSE:CVS) on Friday, September 15. Moriarty Thomas M also sold $7.19 million worth of CVS Health Corporation (NYSE:CVS) shares. MERLO LARRY J sold 241,150 shares worth $20.03M. Denton David M had sold 237,078 shares worth $18.88M on Monday, September 11. Roberts Jonathan C also sold $7.13 million worth of CVS Health Corporation (NYSE:CVS) shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts